$GLSI
Greenwich LifeSciences, Inc.

2024 Q2 Form 10-K Financial Statement

#000149315224014625 Filed on April 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $353.5K $503.1K $1.629M
YoY Change -4.0% 15.23% 4.13%
% of Gross Profit
Research & Development $2.308M $2.333M $7.699M
YoY Change 67.29% -5.09% 18.89%
% of Gross Profit
Depreciation & Amortization $910.00 $3.610K $3.610K
YoY Change 0.0% 301.11% 0.0%
% of Gross Profit
Operating Expenses $2.661M $2.836M $9.328M
YoY Change 52.27% -2.03% 16.01%
Operating Profit -$2.661M -$9.328M
YoY Change 52.27% 16.01%
Interest Expense $54.72K $89.29K $436.1K
YoY Change -54.19% -14.28% 102.8%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.607M -$2.747M -$8.892M
YoY Change 60.08% -1.57% 13.63%
Income Tax
% Of Pretax Income
Net Earnings -$2.607M -$2.747M -$8.892M
YoY Change 60.08% -1.57% 13.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20 -$0.69
Diluted Earnings Per Share -$0.20 -$0.21 -$0.69
COMMON SHARES
Basic Shares Outstanding 12.88M shares 12.85M shares
Diluted Shares Outstanding 12.91M shares 12.85M shares

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.225M $6.989M $6.989M
YoY Change -33.98% -48.1% -48.1%
Cash & Equivalents $7.225M $6.989M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.225M $6.989M $6.989M
YoY Change -33.98% -48.1% -48.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.580K $5.395K $5.400K
YoY Change -50.27% -40.05% -40.0%
TOTAL ASSETS
Total Short-Term Assets $7.225M $6.989M $6.989M
Total Long-Term Assets $3.580K $5.395K $5.400K
Total Assets $7.228M $6.995M $6.995M
YoY Change -34.0% -48.1% -48.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.335M $256.3K $256.3K
YoY Change 344.4% 16.06% 16.06%
Accrued Expenses $17.80K $38.09K $38.09K
YoY Change 1548.15% -9.44% -9.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.353M $294.4K $294.4K
YoY Change 348.7% 11.98% 11.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.353M $294.4K $294.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.353M $294.4K $294.4K
YoY Change 348.7% 11.98% 11.98%
SHAREHOLDERS EQUITY
Retained Earnings -$55.44M -$50.36M
YoY Change 22.59% 21.44%
Common Stock $61.32M $57.06M
YoY Change 9.74% 4.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.875M $6.700M $6.700M
YoY Change
Total Liabilities & Shareholders Equity $7.228M $6.995M $6.995M
YoY Change -34.0% -48.1% -48.1%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.607M -$2.747M -$8.892M
YoY Change 60.08% -1.57% 13.63%
Depreciation, Depletion And Amortization $910.00 $3.610K $3.610K
YoY Change 0.0% 301.11% 0.0%
Cash From Operating Activities -$1.048M -$2.159M -$6.479M
YoY Change 8.36% -0.53% 4.49%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.767M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.048M -2.159M -$6.479M
Cash From Investing Activities
Cash From Financing Activities 2.767M 0.000
Net Change In Cash 1.719M -2.159M -$6.479M
YoY Change -277.76% -0.53% -52.84%
FREE CASH FLOW
Cash From Operating Activities -$1.048M -$2.159M -$6.479M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001799788
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
56572305 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12878409 shares
CY2022 dei Auditor Firm
AuditorFirmId
206
CY2023 dei Auditor Name
AuditorName
RBSM LLP
CY2023 dei Auditor Location
AuditorLocation
Austin, Texas
CY2023 dei Auditor Firm
AuditorFirmId
587
CY2022 dei Auditor Name
AuditorName
MaloneBailey, LLP
CY2022 dei Auditor Location
AuditorLocation
Houston, Texas
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6989424 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13468026 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5391 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9003 usd
CY2023Q4 us-gaap Assets
Assets
6994815 usd
CY2022Q4 us-gaap Assets
Assets
13477029 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
256317 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
38089 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42060 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
294406 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
262905 usd
CY2023Q4 us-gaap Liabilities
Liabilities
294406 usd
CY2022Q4 us-gaap Liabilities
Liabilities
262905 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57052130 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54674042 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50364569 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41472766 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6700409 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6994815 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13477029 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7698622 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6475668 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1629244 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1564586 usd
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
436063 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8891803 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7825237 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12913848 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12913848 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1743865 usd
CY2022 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
7536216 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7825237 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2378088 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8891803 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6700409 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8891803 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7825237 usd
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3612 usd
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
3612 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
2378088 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1743865 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35472 usd
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3971 usd
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-122267 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6478602 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6200027 usd
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7536216 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7536216 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6478602 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13736243 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6989424 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6989424 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zHUaIkl55Pm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zmMGNdKhTJM4">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023 us-gaap Payments For Rent
PaymentsForRent
2582 usd
CY2023 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
the underlying lease expires in May of 2024.
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4505244 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3137364 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4505244 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3137364 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
21500000 usd
CY2023 GLSI Operating Loss Carryforward Expiration Date
OperatingLossCarryforwardExpirationDate
2037
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
220845 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
220845 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
893181 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
893181 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
120 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2009657 usd
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
15181 shares
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34157 usd
CY2023Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2023Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
CY2021Q4 GLSI Issuance Of Common Stock Through Partial Exercise Of Underwriter Warrants
IssuanceOfCommonStockThroughPartialExerciseOfUnderwriterWarrants
562596 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
67230 usd
CY2023Q4 us-gaap Share Price
SharePrice
10.52
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1498128 shares
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.63
CY2023 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
9512356 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.06 pure
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3626584 usd
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5885772 usd
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y

Files In Submission

Name View Source Status
0001493152-24-014625-index-headers.html Edgar Link pending
0001493152-24-014625-index.html Edgar Link pending
0001493152-24-014625.txt Edgar Link pending
0001493152-24-014625-xbrl.zip Edgar Link pending
ex23-1.htm Edgar Link pending
ex23-1_001.jpg Edgar Link pending
ex23-2.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_001.jpg Edgar Link pending
form10-k_002.jpg Edgar Link pending
form10-k_003.jpg Edgar Link pending
form10-k_004.jpg Edgar Link pending
form10-k_005.jpg Edgar Link pending
form10-k_006.jpg Edgar Link pending
form10-k_007.jpg Edgar Link pending
glsi-20231231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
form10-k_htm.xml Edgar Link completed
glsi-20231231_cal.xml Edgar Link unprocessable
glsi-20231231_def.xml Edgar Link unprocessable
glsi-20231231_lab.xml Edgar Link unprocessable
glsi-20231231_pre.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rep_001.jpg Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable